
Serum Institute of India Pvt Ltd (SII) and PATH have achieved a major milestone with the prequalification of MenFive, the first conjugate vaccine to protect against the five major causes of meningococcal meningitis in Africa, by the WHO. The 13-year collaboration, supported by the UK government, aims to eliminate annual meningitis outbreaks in the African meningitis belt. MenFive protects against meningococcal serogroups A, C, W, Y, and X and has demonstrated high levels of safety and efficacy in clinical studies.
Like
Save
Share